SecBot SecBot
6-K ·Filed Jul 6, 2026

IVA

Inventiva S.A.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001171843-26-004459
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine procedural filing with no material financial or operational news. The rejection of the 31st resolution (share capital increase for employee savings plan) is minor and non-dilutive. Monitor the ongoing NATiV3 Phase 3 trial for lanifibranor for the next catalyst — no actionable trading signal from this filing.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
IVA ▼ -15.64% at T+60d
NEUTRAL call -15.64% · α vs SPY -17.36% · entry $3.90 → $3.29
Entry = T+0 close
Jul 6, 2026
via day close
T+1d
+16.92%
call +16.92% · α +17.40%
$4.56
settled 4mo ago
T+5d
+10.26%
call +10.26% · α +9.77%
$4.30
settled 4mo ago
T+20d
+14.87%
call +14.87% · α +15.44%
$4.48
settled 3mo ago
T+60d
-15.64%
call -15.64% · α -17.36%
$3.29
settled 28d ago

Price Chart

Loading chart...

Executive Summary

Inventiva reported the results of its Combined Shareholders General Meeting held June 30, 2026. All 40 resolutions were adopted except the 31st (which would have authorized share capital increases for a company savings plan), which was rejected with 54.06% against. The meeting approved compensation policies and routine governance items with strong quorum of 71.874%. This is a routine procedural filing with no material financial or operational impact.

Key Facts

  • All 40 resolutions adopted except the 31st (share capital increase for savings plan), which was rejected with 54.06% against
  • Quorum of 71.874% of share capital represented
  • Total shares outstanding: 236,280,202
  • Shareholders approved compensation policy for corporate officers without modification

Financial Impact

No financial impact — routine shareholder meeting vote results with no material financial disclosures

Risk Factors

  • No material risks disclosed in this filing beyond standard forward-looking statements

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-004459
Document: f6k_070226.htm0001171843-26-004459
Document: 0001171843-26-004459-index-headers.html0001171843-26-004459
Document: 0001171843-26-004459-index.html0001171843-26-004459
Document: 0001171843-26-004459.txt0001171843-26-004459
6 reports for IVA
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for IVA — sortable, filterable
TypeNow
Oct 6, 2026
20d ago
6-K
NEUTRAL ★ 3/10
$3.37awaiting T+20—$3.80 (+12.93%)
Sep 28, 2026
29d ago
6-K
MIXED ★ 6/10
$3.53 $3.66▲ +3.68%▲ +3.71%$3.80 (+7.65%)
Sep 3, 2026
7w ago
6-K
BULLISH ★ 7/10
$4.84 $3.56▼ −26.45%▼ −25.26%$3.80 (−21.49%)
Jul 6, 2026
16w ago
6-K
NEUTRAL ★ 2/10
$3.90 $4.48▲ +14.87%▲ +15.44%$3.80 (−2.56%)
Jun 12, 2026
19w ago
6-K
MIXED ★ 6/10
$3.76 $4.30▲ +14.36%▲ +15.11%$3.80 (+1.06%)
Jun 12, 2026
19w ago
6-K
NEUTRAL ★ 3/10
$3.85 $4.30▲ +11.69%▲ +9.91%$3.80 (−1.30%)
Showing 6 of 6

US Market Status

Market Open — Closes in 5h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 6, 2026